IN-VITRO EVALUATION OF ABT-719, A NOVEL DNA GYRASE INHIBITOR

ABT-719 (A-86719.1) is the first compound of a new class of novel DNA gyrase inhibitors, the 2-pyridones, with potent antibacterial activity against gram-positive, gram-negative, and anaerobic organisms. ABT-71 9 was more active than ciprofloxacin, sparfloxacin, and clinafloxacin against gram-positive bacteria. ABT-719 ws particularly active against Staphylococcus aureus (MIC at which 90% of the isolates were inhibite d [MIC(90)] = 0.015 mu g/ml) and Streptococcus pneumoniae (MIC = 0.03 mu g/ml). ABT-719 ws also the most active of the compounds tested agai nst ciprofloxacin-resistant S. aureus isolates, with an MIC(90) of 0.2 5 mu g/ml, compared with 64 mu g/ml for ciprofloxacin. Against gram-ne gative organisms, ABT-719 was as active or slightly more active than c iprofloxacin and was the most active compound against both gram-positi ve and gram-negative anaerobes, with MIC(90)s ranging from 0.12 to 0.2 5 mu g/ml.